




RealRate

PHARMACEUTICAL 2016

Juniper Pharmaceuticals INC
Rank 103 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Juniper Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Juniper Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 59% points. The greatest weakness of Juniper Pharmaceuticals INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 333%, being 70% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	25,934
Cost of Goods Sold	21,414
Intangible Assets	11,608
Liabilities, Current	9,839
Liabilities, Non-Current	0
Other Assets	185
Other Compr. Net Income	-1,099
Other Expenses	1,254
Other Liabilities	3,676
Other Net Income	382
Other Revenues	38,287
Property and Equipment	12,850
Research and Development	7,039
Selling, General and Administrative Expense	10,458

Output Variable	Value in 1000 USD
Assets	50,577
Liabilities	13,515
Expenses	40,165
Revenues	38,287
Stockholders Equity	37,062
Net Income	-1,496
Comprehensive Net Income	-2,046
BaseVar	72,012
ECR before LimitedLiability	246%
Economic Capital Ratio	333%